Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice.

Department of Internal Medicine and The Institute of Hypertension, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Diabetes (Impact Factor: 8.47). 04/2010; 59(4):997-1005. DOI: 10.2337/db09-1241
Source: PubMed

ABSTRACT Accumulating evidence suggests that cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids (EETs), which play crucial and diverse roles in cardiovascular homeostasis. The anti-inflammatory, antihypertensive, and pro-proliferative effects of EETs suggest a possible beneficial role for EETs on insulin resistance and diabetes.
This study investigated the effects of CYP2J3 epoxygenase gene therapy on insulin resistance and blood pressure in diabetic db/db mice and in a model of fructose-induced hypertension and insulin resistance in rats.
CYP2J3 gene delivery in vivo increased EET generation, reduced blood pressure, and reversed insulin resistance as determined by plasma glucose levels, homeostasis model assessment insulin resistance index, and glucose tolerance test. Furthermore, CYP2J3 treatment prevented fructose-induced decreases in insulin receptor signaling and phosphorylation of AMP-activated protein kinases (AMPKs) in liver, muscle, heart, kidney, and aorta. Thus, overexpression of CYP2J3 protected against diabetes and insulin resistance in peripheral tissues through activation of insulin receptor and AMPK pathways.
These results highlight the beneficial roles of the CYP epoxygenase-EET system in diabetes and insulin resistance.


Available from: Matthew L Edin, Mar 19, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Skeletal muscle microvascular blood flow (MBF) increases in response to physiologic hyperinsulinemia. This vascular action of insulin may facilitate glucose uptake. We hypothesized that epoxyeicosatrienoic acids (EETs), a family of arachadonic acid-derived endothelium-derived hyperpolarizing factors, is a mediator of insulin's microvascular effects. Contrast-enhanced ultrasound (CEU) was performed to quantify skeletal muscle capillary blood volume (CBV) and MBF in wild-type and obese insulin-resistant (db/db) mice after administration of vehicle or tAUCB, an inhibitor of soluble epoxide hydrolase which converts EETs to less active dihydroxyeicosatrienoic acids. Similar studies were performed in rats pre-treated with L-NAME. CEU was also performed in rats undergoing a euglycemic hyperinsulinemic clamp, half of which were pre-treated with the epoxygenase inhibitor MS-PPOH to inhibit EET synthesis. In both wild type and db/db mice, intravenous tAUCB produced an increase in CBV (65-100% increase at 30 min, p<0.05) and in MBF. In db/db/ mice tAUCB also reduced plasma glucose by approximately 15%. In rats pretreated with L-NAME, tAUCB after produced a significant ≈20% increase in CBV indicating a component of vascular response independent of nitric oxide (NO) production. Hyperinsulinemic clamp produced a time-dependent increase in MBF (19±36 and 76±49% at 90 min, p=0.026) mediated in part by an increase in CBV. Insulin-mediated changes in both CBV and MBF during the clamp were entirely blocked MS-PPOH. We conclude that EETs are a mediator of insulin-mediated augmentation in skeletal muscle perfusion and are involved in regulating changes in CBV during hyperinsulinemia.
    AJP Endocrinology and Metabolism 10/2014; 307(12):ajpendo.00216.2014. DOI:10.1152/ajpendo.00216.2014 · 4.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the last 20 years, it has become clear that cytochrome P450 (P450) enzymes generate a spectrum of bioactive lipid mediators from endogenous substrates. However, studies focused on the determining biologic activity of the P450 system have focused largely on the metabolites generated by one substrate (i.e., arachidonic acid). However, epoxides and diols derived from other endogenous substrates, such as linoleic acid, eicosapentaenoic acid, and docosahexaenoic acid, may be generated in higher concentrations and may potentially be of more physiologic relevance. Recent studies that used a combination of phenotyping and lipid array analyses revealed that rather than being inactive products, fatty acid diols play important roles in a number of biologic processes including inflammation, angiogenesis, and metabolic regulation. Moreover, inhibitors of the soluble epoxide hydrolase that increase epoxide but decrease diol levels have potential for the treatment of the metabolic syndrome.
    Pharmacological reviews 10/2014; 66(4):1106-1140. DOI:10.1124/pr.113.007781 · 18.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and Purpose: Epoxyeicosatrienoic acids (EETs), arachidonic acid-derived cytochrome P450 (CYP) epoxygenase metabolites, have diverse biological effects including anti-inflammatory properties in the vasculature. Increasing evidence suggests that inflammation in type 2 diabetes is a key component in the development of insulin resistance. Experimental Approach: In this study, we investigated if CYP epoxygenase expression and exogenous EETs can attenuate insulin resistance in diabetic db/db mice and in cultured hepatic cells (HepG2). In vivo, CYP2J2 expression and the accompanying increase in EETs attenuated insulin resistance as determined by plasma glucose levels, glucose tolerance test, insulin tolerance test, and hyperinsulinemic-euglycemic clamp studies. Key Results: CYP2J2 expression reduced the production of pro-inflammatory cytokines in liver, including CRP, IL-6, IL-1β and TNF-α, and decreased the infiltration of macrophages in liver. CYP2J2 expression also decreased activation of pro-inflammatory signaling cascades by decreasing NF-κB and MAPK activation in hepatocytes. Interestingly, CYP2J2 expression and exogenous EET treatment increased glucose uptake and activated the insulin signaling cascade both in vivo and in vitro, suggesting that CYP2J2 metabolites play a role in glucose homeostasis. Furthermore, CYP2J2 expression up-regulated PPARγ, which has been shown to induce adipogenesis that attenuate dyslipidemias observed in diabetes. Conclusions & Implications: All the findings suggest that CYP2J2 expression attenuates the diabetic phenotype and insulin resistance via inhibition of NF-κB and MAPK signaling pathways, and activation of PPARγ.
    AJP Endocrinology and Metabolism 11/2014; 308(4):ajpendo.00118.2014. DOI:10.1152/ajpendo.00118.2014 · 4.09 Impact Factor